|本期目录/Table of Contents|

[1]吴雨征,杨 同,安泽生,等.单中心214例非肌层浸润性膀胱癌复发因素分析[J].天津医科大学学报,2016,22(06):516-519.
 WU Yu-zheng,YANG Tong,AN Ze-sheng,et al.Exploring the risk factors of recurrence in 214 patients with non-muscle invasive bladder cancer by retrospectively analysis [J].Journal of Tianjin Medical University,2016,22(06):516-519.
点击复制

单中心214例非肌层浸润性膀胱癌复发因素分析(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
22卷
期数:
2016年06期
页码:
516-519
栏目:
临床医学
出版日期:
2016-11-20

文章信息/Info

Title:
Exploring the risk factors of recurrence in 214 patients with non-muscle invasive bladder cancer by retrospectively analysis
文章编号:
1006-8147(2016)06-0516-4
作者:
吴雨征杨 同安泽生薄志强张洪团张昌文徐 勇
(天津医科大学第二医院泌尿外科;天津市泌尿外科研究所,天津 300211)
Author(s):
WU Yu-zheng YANG Tong AN Ze-sheng BO Zhi-qiang ZhANG Hong-tuan ZhANG Chang-wen XU Yong
(Department of Urology, The Second Hospital ,Tianjin Medical University,Tianjin Institute of Urology,Tianjin 300211,China)
关键词:
膀胱肿瘤复发风险因素
Keywords:
urinary bladder neoplasms recurrence risk factors
分类号:
737.14
DOI:
-
文献标志码:
A
摘要:
目的:分析影响非肌层浸润性膀胱癌复发的风险因素及其临床意义。方法:回顾分析214例非肌层浸润性膀胱癌患者的全部临床资料,对性别,年龄,体质量指数,是否合并高血压、糖尿病,肿瘤数量、大小(多发肿瘤以最大肿瘤直径定义)、分期、组织学分级,术后是否即刻灌注治疗,静脉化疗等因素进行生存分析,初次复发或进展为终点事件,运用Log-Rank检验,Kaplan-Meier法单因素分析比较各因素无病生存率差异,Cox比例风险回归模型多因素分析复发的独立风险因素。结果:214例非肌层浸润性膀胱癌患者平均就诊年龄68.5岁,男:女=1.4:1,随访时间8~48个月,复发63例(总复发率29.3%)。单因素分析发现,肿瘤数目,肿瘤大小,肿瘤分级,肿瘤分期,是否行即刻膀胱灌注治疗与复发相关有统计学意义(均P<0.05)。多因素分析显示,肿瘤数目,肿瘤大小,肿瘤分级,肿瘤分期,是否行即刻膀胱灌注治疗是非肌层浸润性膀胱癌复发的独立预测因子。结论:肿瘤数目,肿瘤大小,肿瘤分级,肿瘤分期是非肌层浸润性膀胱癌复发的独立风险因素。膀胱即刻灌注是非肌层浸润性膀胱癌的保护因素。
Abstract:
Objective To explore the main influencing factors and clinical significance of the recurrence of non-muscle invasive bladder cancer (NMIBC). Methods: Two hundred and fourteen patients with NMIBC were retrospectively reviewed in single center. Gender, age,BMI ,hypert-ension,diabetes,tumor size, tumor number, tumor grade, tumor stage, immediately intravesical instillation and intravesical chemotherapy were predicted to be the risk factors.Survival analysis was carried out by employing Kaplan-Meier and Cox proportional hazard model. Results: Finally 214 patients with NMIBC were studied, with mean age of 68.5 years at presentation, and male to female ratio was 1.4∶1. Based on 8-48 months of following up, 63(29.3%) of 214 cases had recurrence .Univariate analysis indicated that number, size, grade and stage of tumor and immediate intravesical instillation were significantly associated with the recurrence of NMIBC (all P<0.05). Number, size, grade and stage of tumor and immediate intravesical instillation were independent risk factors for recurrence of NMIBC. Conclusion: number, size, grade and stage of tumor are the independent risk factors for recurrence of NMIBC. Immediate intravesical instillation is protective for recurrence of NMIBC.

参考文献/References:

[1]Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J].CA Cancer J Clin,2016,66(2):115
[2]Burger M, Catto J W, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder ancer[J].Eur Urol,2013,63(2):234
[3]Kurth K H, Denis L, Bouffioux C, et al. Factors affecting recurrence and progression in superficial bladder tumours[J].Eur J Cancer,1995,31A(11):1840
[4]Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model[J].J Urol,2009,182(5):2195
[5]Sylvester R J, van der Meijden A P, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials[J].Eur Urol,2006,49(3):465
[6]Rieken M, Xylinas E, Kluth L, et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer[J].BJU Int,2013,112(8):1105
[7]Hwang E C, Kim Y J, Hwang I S, et al. Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study[J].Int J Urol,2011,18(11):769
[8]Hwang I, Jung S I, Nam D H, et al. Preoperative hydronephrosis and diabetes mellitus predict poor prognosis in upper urinary tract urothelial carcinoma[J].Can Urol Assoc J,2013,7(3/4):E215
[9]Masur K, Vetter C, Hinz A, et al. Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation[J].Br J Cancer,2011,104(2):345
[10]Turturro F, Friday E, Welbourne T. Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin- interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231[J].BMC Cancer,2007,7:96
[11]García-Jiménez C, García-Martínez J M, Chocarro-Calvo A, et al. A new Link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose[J].J Mol Endocrinol,2014,52(1):R51
[12]Krone C A, Ely J T.Controlling hyperglycemia as an adjunct to cancer therapy[J].Integr Cancer Ther,2005,4(1):25
[13]Heidari F, Abbas Z S, Mir H H, et al. Metformin for the prevention of bladder cancer recurrence:is it effective[J].Nephrourol Mon,2016
[14]Patel T, Hruby G, Badani K, et al. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin[J]. Urology,2010,76(5):1240
[15]Kluth L A, Xylinas E, Crivelli J J, et al. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder[J].J Urol,2013,190(2):480
[16]Bianchini F, Kaaks R, Overweight V H. Obesity,and Cancer risk[J].Lancet Oncol,2002,3(9):565
[17]Blanchard C M, Stein K, Courneya K S. Body mass index, physical activity, and health-related quality of Life in cancer survivors[J].Med Sci Sports Exerc,2010,42(4):665
[18]Keimling M, Behrens G, Schmid D, et al. The association between physical activity and bladder Cancer: systematic review and meta-analysis[J].Br J Cancer,2014,110(7):1862
[19]Sonpavde G, Watson D, Tourtellott M, et al. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community[J].Clin Genitourin Cancer,2012,10(1):1
[20]Carles J,Esteban E, Climent M, et al. Gemcitabine and oxaliplatin combination:a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer[J].Annals of Oncology,2007,18(8):1359
[21]Takaoka E I, Matsui Y, Inoue T, et al. Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era[J].Jpn J Clin Oncol,2013,43(4):404
[22]Soukup V, Du?ková J, Pe?l M, et al. The prognostic value of T1 bladder cancer substaging: a single institution retrospective study[J].Urol Int,2014,92(2):150
[23]Liu S, Hou J, Zhang H, et al. The evaluation of the risk factors for non-muscle invasive bladder cancer (NMIBC) recurrence after transurethral resection (TURBt) in Chinese population[J].PLoS One,2015,10(4):e0123617
[24]Hu Z, Mudaliar K, Quek M L, et al. Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence[J].Ann Diagn Pathol,2014,18(2):49
[25]Okamura K, Ono Y, Kinukawa T, et al. Randomized study of single early instillation of (2"R)-4’-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma[J].Cancer,2002,94(9):2363
[26]Perlis N, Zlotta A R, Beyene J, et al. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review[J].Eur Urol,2013,64(3):421
[27]Chamie K, Litwin M S, Bassett J C, et al. Recurrence of high-risk bladder Cancer: a population-based analysis[J]. Cancer, 2013, 119 (17):3219

相似文献/References:

[1]栾祖乾,李春风,杨 龙,等.经尿道2μm激光膀胱部分切除治疗膀胱肿瘤65例报告[J].天津医科大学学报,2014,20(04):297.
 LUAN Zu-qian,LI Chun-feng,YANG Long,et al.Transurethral partial cystectomy with 2μm lasert for bladder tumors: a report of 65 cases [J].Journal of Tianjin Medical University,2014,20(06):297.
[2]何 振,徐 勇,齐士勇,等.尿路上皮癌伴鳞状分化对TURBT术后pT1期患者预后的影响[J].天津医科大学学报,2016,22(03):213.
 HE Zhen,XU Yong,QI Shi-yong,et al.Influence?of squamous differentiation on prognosis?of patients with pT1 urothelial carcinoma of bladder after TURBT[J].Journal of Tianjin Medical University,2016,22(06):213.
[3]王丽宁,范晓东,孙二琳,等.重组hIFN-α-2b-BCG抗肿瘤效应的体外研究[J].天津医科大学学报,2016,22(05):377.
 WANG Li-ning,FAN Xiao-dong,SUN Er-lin,et al.Study on antitumor effect of recombinant hIFN-α-2b-BCG in vitro[J].Journal of Tianjin Medical University,2016,22(06):377.
[4]刘 豫,薄志强,张志宏.糖尿病及二甲双胍对上尿路肿瘤术后复发的影响[J].天津医科大学学报,2017,23(01):53.
 LIU Yu,BO Zhi-qiang,ZHANG Zhi-hong.Effect of diabetes mellitus and metformin on intravesical recurrence after radical operation in patients with upper urinary tract urothelial carcinoma[J].Journal of Tianjin Medical University,2017,23(06):53.
[5]张姝阳,张家丽,赵 宁,等.IP方案与CAO方案二线治疗复发小细胞肺癌的疗效及毒副作用比较研究[J].天津医科大学学报,2018,24(05):415.
 ZHANG Shu-yang,ZHANG Jia-li,ZHAO Ning,et al.Comparison of the efficacy and toxicity between the IP regimen and the CAO regimen in the second line treatment for recurrent small cell lung cancer[J].Journal of Tianjin Medical University,2018,24(06):415.

备注/Memo

备注/Memo:

作者简介 吴雨征(1991-),男,硕士在读,研究方向:泌尿外科;

通信作者:徐勇,E-mail:xuyong8816@sina.com

更新日期/Last Update: 2016-11-25